Mannose: A Sweet Option in the Treatment of Cancer and Inflammation

Fang Nan, Yutong Sun, Hantian Liang, Jingyang Zhou, Xiao Ma and Dunfang Zhang*

Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

As a natural sugar, mannose is a type of hexose that is abundant in many different types of fruits. Since mannose is rarely used for glycolysis in mammals, studies on the role of mannose have not attracted much attention. Glycosylation of specific proteins was thought to be the major function of mannose. Surprisingly, during the past few years, mannose was found to be effective in promoting immune tolerance and suppressing inflammatory diseases related to autoimmunity and allergy. Moreover importantly, mannose was also found to be efficient in suppressing tumors by suppressing glycolysis and enhancing chemotherapeutic agents. In this review, we summarize the recent studies of mannose on antitumor properties and anti-inflammatory characteristics. We emphasize that mannose could play a beneficial role in the treatment of a variety of diseases, including cancers and inflammatory diseases, and could be a novel therapeutic strategy that deserves continued evaluation.

Keywords: mannose, treg cells, autoimmune disorders, tumor therapy, mannose phosphate isomerase, glycolysis

INTRODUCTION

In recent years, the general public has paid more and more attention to the relationship between diet and disease. Adjusting diet has also been shown to enhance cancer treatment (Kanarek et al., 2020; Tajan and Vousden, 2020). Among the hexoses people consume on a daily basis, mannose appears to be the most attractive in many ways. Mannose is a hexose, which is a component of many polysaccharides. Mannose is poorly metabolized in the human body, so it is not obvious that mannose enters carbohydrate metabolism after oral administration. Mannose plays an important role in human metabolism, especially in glycosylation of certain proteins (Alton et al., 1998) involved in immune regulation. Congenital glycosylation disorder (CDG) is a kind of disorder that is difficult to diagnose clinically due to its various manifestations and abnormal functions of multiple organ systems (Jaeken and Péanne, 2017; Péanne et al., 2018). CDG-Ib (MPI-CDG) is caused by mutations in mannose phosphate isomerase (MPI) (Freeze and Sharma, 2010). Based on the fact that MPI deletion can lead to liver fibrosis (Janssen et al., 2014), DeRossi et al. conducted experiments with zebrafish as a model, and observed that MPI deletion in zebrafish larvae can lead to liver development defects (DeRossi et al., 2019). They demonstrated that acute and persistent MPI deletions are sufficient to activate hematopoietic stem cells and induce fibrosis in vitro and in whole vertebrate models, suggesting that MPI deletions promote stellate cell activation. Direct production of mannose-6-phosphate based on mannose phosphorylation circumvented the MPI defect (Niehues et al., 1998; Lonlay and Seta, 2009), and together with experimental results, showed that mannose reduced stellate cell activation and fibrosis.

During the last few years, mannose has been shown to have many physiological benefits and applications, such as suppressing inflammation (Zhang et al., 2021), and suppressing tumor growth and metastasis (Gonzalez et al., 2018). Besides suppressing Type 1 diabetes, asthma and macrophage-
mediated inflammation (Zhang et al., 2017; Torretta et al., 2020), a most recent study has shown that mannose can suppress experimental autoimmune encephalomyelitis (EAE) by inducing treg cells, suggesting that Mannose may be a potential adjuvant therapy for multiple sclerosis (MS) (Hwang et al., 2021). More importantly, mannose has been determined to be effective in suppressing different kinds of cancers (Gonzalez et al., 2018). This review focuses on the research progress of mannose in treating tumors and inflammation. We emphasize the potential of mannose as a therapeutic agent for the above-mentioned diseases and raise questions to be addressed.

THE ANTICANCER EFFECTS OF MANNOSE

**Mannose Interferes With Glucose Metabolism of Tumor Cells**

Tumor cells usually have a high demand and affinity for glucose (Bhattacharya et al., 2016). Based on the fact that mannose and glucose are introduced into cells by the same transporters (Thorens and Mueckler, 2010), Gonzalez et al. have proposed that mannose may interfere with glucose uptake by tumor cells, and made relevant experimental verification (Gonzalez et al., 2018). Interestingly, the results showed that mannose treatment did not reduce or even increase the intracellular glucose level, but affected cell growth by interfering with glucose metabolism (Gonzalez et al., 2018). The mechanism at hand is that mannose accumulates in the form of mannose-6-phosphate and the accumulation of M6P suppresses glucose phosphate isomerase (GPI) and other enzymes related to glucose metabolism, resulting in inhibition of glycolysis and in turn inhibition of the tricarboxylic acid cycle (TCA). In contrast, in tumor cells that express a high level of MPI, mannose could be used for glycolysis efficiently. Recent studies have found that Zn²⁺ is crucial for mannose phosphate isomerase (PMI) to exert enzymatic activity, and when ZIP10, a transporter of Zn²⁺, is knocked down, it causes the inactivation of PMI and makes tumor cells become mannose sensitive.

**FIGURE 1** Mannose interferes with glucose metabolism in tumor cells with low expression of the MPI gene. Mannose and glucose are transported into cells by the same transporter (GLUT), and transformed by hexokinase (HK) into mannose-6-phosphate (M6P) and glucose-6-phosphate (G6P). In those tumor cells with low mannose phosphate isomerase (MPI) expression, the accumulation of M6P suppresses glucose phosphate isomerase (GPI) and other enzymes related to glucose metabolism, resulting in inhibition of glycolysis and in turn inhibition of the tricarboxylic acid cycle (TCA). In contrast, in tumor cells that express a high level of MPI, mannose could be used for glycolysis efficiently. Recent studies have found that Zn²⁺ is crucial for mannose phosphate isomerase (PMI) to exert enzymatic activity, and when ZIP10, a transporter of Zn²⁺, is knocked down, it causes the inactivation of PMI and makes tumor cells become mannose sensitive.
appropriate dosage that has maximum effectiveness without any significant side effect. Based on the above mechanisms, a recent study has shown that mannose inhibits cell proliferation and enhances radiation-induced apoptosis in human esophageal squamous carcinoma cells with low MPI expression in a dose-dependent manner (Luo et al., 2022). This suggests that mannose can act as a radiation sensitizer in patients with esophageal squamous cell carcinoma with low MPI expression. There is also a study showed that in the early and middle stages of the development of glioblastoma multiforme (GBM), mannose can be combined with temozolomide concurrent radiotherapy (RT/TMZ) to achieve cure (Liu et al., 2020).

**Inhibitory Effect of Mannose on Various Tumors**

For thyroid cancer, one recent study has found that whether the cell line is sensitive to mannose depends mainly on the enzyme activity of PMI (Ma et al., 2021). Structurally, zinc ions (Zn²⁺) are critical for the binding of the PMI and substrate, so the enzymatic function of PMI depends on Zn²⁺ concentration (Bangera et al., 2019). ZIP10 is a Zn²⁺ transporter expressed during early B cell development that transports Zn²⁺ from outside the cell to the cytoplasm, thereby altering the concentration of Zn²⁺ within the cell (Miyai et al., 2014). The latest study found that in thyroid cancer cells that are not sensitive to mannose, knocking down ZIP10 can significantly improve their sensitivity to mannose, and M6P accumulation in turn enhances the inhibitory effect of mannose on cellular glycolysis (Ma et al., 2021) (Figure 1). These findings suggest that mannose has potential application value in the treatment of thyroid cancer.

In non-small cell carcinoma (NSCLC), it has been proved that mannose has a significant inhibitory effect on the proliferation, invasion, and metastasis of A549 cells. Mannose was shown to be able to induce G0/G1 arrest by down-regulating the expression of PCNA and up-regulating the expression of p21, both of which are related to the concentration of mannose (Wang et al., 2020). Moreover, mannose can promote the expression of phosphorylated GSK-3β, suppress the activation of ERK, and thereby reduce the expression of β-catenin and SNAIL, which in turn reduce N-cadherin and increases E-cadherin, thereby suppressing tumor metastasis (Wang et al., 2020; Luo et al., 2020) (Figure 2). In terms of mechanism, epithelial-mesenchymal transition (EMT) plays an indispensable role in cancer metastasis (Heerboth et al., 2015). Several transcription factors are upregulated in EMT metastatic cells, represented by SNAIL. SNAIL can be combined with the E-cadherin promoter to suppress the expression of E-cadherin and promote EMT (Al Khatib et al., 2021).
Phagocytosis of DC cells, and promotes specific T cell anti-tumor immunity (Ma et al., 2022). The study also showed that the mannose released by DMNG interferes with glucose metabolism and thus regulates tumor metabolism, ultimately leading to apoptosis of cancer cells. It is also pointed out that this strategy can systematically modulate the tumor microenvironment (TME) and improve the immunosuppressive tumor microenvironment (ITM).

**THE ANTI-INFLAMMATORY EFFECTS OF MANNOSE**

Besides the anticancer effects, mannose has been proven to suppress inflammation by suppressing glycolysis, promoting TGF-β activation and inducing Treg cells (Zhang et al., 2017; Torretta et al., 2020). Since it has been well summarized in the recent past that mannose is a novel suppressor of inflammation (Zhang et al., 2021), we only emphasize the point that mannose treatment could be a safe and promising strategy to suppress and to treat autoimmunity and asthma. More than that, mannose could also suppress wound-inducing inflammation in skin (Jokela et al., 2013). Hyaluronic acid (HA) is the only non-sulfated glycosaminoglycan in the extracellular matrix (Genasetti et al., 2008). It is involved in endothelial cell proliferation, migration, neovascularization, and leukocyte recruitment, and its metabolism is significantly altered in inflammation (Tammi et al., 2005). During inflammatory stimulation, the HA receptor, CD44, on the surface of leukocytes binds to the HA cable structure (La Motte et al., 1999; La Motte et al., 2003). In vitro, it has been reported that mannose consumes UDP GlcNAc to reduce the synthesis of HA (Jokela et al., 2008). Tiina et al. found that mannose also reduced the content of HA in vivo and prevented the binding of leukocytes to HA on the cell surface (Jokela et al., 2013). Not only that, they also found IL-1β induces the HA shell in keratinocytes to reconstitute the cable structure, and mannose can inhibit the binding of HA dependent monocytes to keratinocytes. They also found that mannose could suppress the function of dermal fibroblasts, and this potential anti-fibrosis effect needs to be verified by further in vivo experiments.

**CONCLUSION AND FUTURE PERSPECTIVE**

Mannose is used in a variety of daily processes mainly because of its low heat and non-toxic characteristics (Wu et al., 2019). It also has the potential for clinical application in drug therapy (Wei et al., 2020). Mannose has shown anti-tumor effects against a variety of tumors, and it is safe in humans at certain concentrations (Gonzalez et al., 2018). In terms of dosage, a person would need to ingest very large amounts of mannose to match the amounts that were given to the mice in the experiments. Therefore, it is critical to find a way to effectively use mannose for human disease treatment.

In addition, related studies have shown that mannose is a biomarker of insulin resistance, which may help in the early identification of patients with insulin resistance and who are more prone to diabetic complications (Ferrannini et al., 2020). It was also found that plasma mannose levels increased in patients with insulin resistance independently of obesity (Mardinoglu et al., 2017). They confirmed that elevated plasma mannose levels were a strong marker for the risk of chronic diseases such as cardiovascular disease and type 2 diabetes.
2 diabetes and may contribute to their development, although the exact mechanism remains unclear (Mardinoglu et al., 2017). These evidence shows that mannose might have important applications in disease screening and detection.

In conclusion, mannose therapy is expected to be a promising strategy for the treatment of cancer and inflammatory diseases, although it is still needed to fully elucidate the mechanism and accurately evaluate and determine its effective dose in humans.

**AUTHOR CONTRIBUTIONS**

FN wrote the manuscript. YS, HL, JZ and XM edited the manuscript. DZ supervised the work, and edited the manuscript. All authors contributed to the article and approved it for publication.

**REFERENCES**

Al Khatib, A. M., Márgritescu, C., Taiscescu, O., Andreiana, B. C., Florescu, M. M., and Ciurea, R. N. (2019). Immunoexpression of E-Cadherin, Snail and Twist in Colonic Adenocarcinomas. Rom. J. Morphol. Embryol. 60, 531.

Alton, G., Hasilik, M., Niehues, R., Panneerselvam, K., Etchison, J. R., Fana, F., et al. (1998). Direct Utilization of Mannose for Mammalian Glycoprotein Biosynthesis. Glycobiology 8, 285–295. doi:10.1093/glycob/8.3.285

Bangera, M., Gowda K. G., Sagurthi, S. R., and Murthy, M. R. N. (2019). Structural and Functional Insights into Phosphomannose Isomerase: the Role of Zinc and Catalytic Residues. Acta Crystallogr. D. Struct. Biol. 75, 475–487. doi:10.1107/S2059798319004169

Bhattacharya, B., Mohd Omar, M. F., and Soong, R. (2016). The Warburg Effect and Drug Resistance. Br. J. Pharmacol. 173, 970–979. doi:10.1111/bph.13422

de La Motte, C. A., Hascall, V. C., Calabro, A., Yen-Lieberman, B., and Strong, S. A. (1999). Mononuclear Leukocytes Preferentially Bind via CD44 to Hyaluronan on Human Intestinal Mucosal Smooth Muscle Cells after Virus Infection or Treatment with poly(LC). J. Biol. Chem. 274, 30747–30755. doi:10.1074/jbc.274.43.30747

de la Motte, C. A., Hascall, V. C., Drazba, J., Bandyopadhyay, S. K., and Strong, S. A. (2003). Mononuclear Leukocytes Bind to Specific Hyaluronan Structures on Colon Mucosal Smooth Muscle Cells Treated with Polyinosinic Acid-polycytidylic Acid: Inter-alpha-trypsin Inhibitor Is Crucial to Structure and Function. Am. J. Pathol. 163, 121–133. doi:10.1016/S0002-9440(10)63636-X

de Lonlay, P., and Seta, N. (2009). The Clinical Spectrum of Phosphomannose Isomerase Deficiency, with an Evaluation of Mannose Treatment for CDG-Ib. Biochim. Biophys. Acta 1792, 841–843. doi:10.1016/j.bbadis.2008.11.012

DeRossi, C., Bambino, K., Morrison, J., Sakaran, I., Villacorta-Martin, C., Zhang, C., et al. (2019). Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology 70, 2107–2122. doi:10.1002/hep.30877

Ferrannini, E., Bokarewa, M., Brembeck, P., Babootta, R., Hedjazifar, S., Andersson, K., et al. (2020). Mannose Is an Insulin-Regulated Metabolite Reflecting Whole-Body Insulin Sensitivity in Man. Metabolism 102, 153974. doi:10.1016/j.metabol.2019.153974

Freeze, H. H., and Sharma, V. (2010). Metabolic Manipulation of Glycosylation Disorders in Humans and Animal Models. Semin. Cell Dev. Biol. 21, 655–662. doi:10.1016/j.semcdb.2010.03.011

Genasetti, A., Vigetti, D., Viola, M., Karousou, E., Moretto, P., Rizzi, M., et al. (2008). Hyaluronan and Human Endothelial Cell Behavior. Connect. Tissue Res. 49, 120–123. doi:10.1080/03008280802148462

Geng, F., Jiang, Z., Song, X., Zhou, H., and Zhao, H. (2017). Mdig Suppresses Epithelial-Mesenchymal Transition and Inhibits the Invasion and Metastasis of Non small Cell Lung Cancer via Regulating GSK-3β/β-Catenin Signaling. Int. J. Oncol. 51, 1898–1908. doi:10.3892/ijo.2017.4154

**FUNDING**

This work was supported by the National Natural Science Foundation of China (NO. 82171829), the Key Project of the Science and Technology Department of Sichuan Province (NO. 2022YFH0100), the 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (NO. ZYYC2102), and the Fundamental Research Funds for the Central Universities (20822041E4084).

**ACKNOWLEDGMENTS**

DZ sincerely wants to commemorate Dr. Sang-A Park, who passed away suddenly on January 22, 2018.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (NO. 82171829), the Key Project of the Science and Technology Department of Sichuan Province (NO. 2022YFH0100), the 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (NO. ZYYC2102), and the Fundamental Research Funds for the Central Universities (20822041E4084).

**ACKNOWLEDGMENTS**

DZ sincerely wants to commemorate Dr. Sang-A Park, who passed away suddenly on January 22, 2018.
Okae, S., Tanaka, Y., and Gotoh, A. (2021). Effect of D-Mannose on Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., Miyai, T., Hojyo, S., Ikawa, T., Kawamura, M., Irié, T., Ogura, H., et al. (2014). Zinc Frontiers in Pharmacology | www.frontiersin.org May 2022 | Volume 13 | Article 877543

Martinez-Pomares, L. (2012). The Mannose Receptor. J. Leukoc. Biol.

Mardinoglu, A., Stančíková, A., Lotta, L. A., Kuusisto, J., Boren, J., Blüher, M., et al. (2017). Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease. Cell Metab. 26, 281–283. doi:10.1016/j.cmet.2017.07.006

Martinez-Pomares, L. (2012). The Mannose Receptor. J. Leukoc. Biol. 92, 1177–1186. doi:10.1189/jlb.0512231

Miyai, T., Hoyyo, S., Ikawa, T., Kawamura, M., Irié, T., Ogura, H., et al. (2014). Zinc Transporter SLC39A10/ZIP10 Facilitates Antiapoptotic Signaling during Early B-Cell Development. Proc. Natl. Acad. Sci. U. S. A. 111, 11780–11785. doi:10.1073/pnas.1323549111

Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., et al. (1998). Carbohydrate-deficient Glycoprotein Syndrome Type Ib. Phosphomannose Isomerase Deficiency and Mannose Therapy. J. Clin. Invest. 101, 1414–1420. doi:10.1172/JCI2350

Okabe, S., Tanaka, Y., and Gotoh, A. (2021). Effect of D-Mannose on Philadelphia Chromosome-Positive Leukemia Cells. Cbm. 1–10. doi:10.3233/CBM-210141

Péanne, R., de Lonlay, P., Foulquier, F., Kornak, U., Lefeber, D. J., Morava, E., et al. (2018). Congenital Disorders of Glycosylation (CDG): Quo Vadis? Eur. J. Med. Genet. 61, 643–663. doi:10.1172/ejmg.2017.10.012

Sha, J., Cao, D., Cui, R., Xia, L., Hua, X., Lu, Y., et al. (2020). Mannose Impairs Lung Adenocarcinoma Growth and Enhances the Sensitivity of A549 Cells to Carboplatin. Cancer Manag. Res. 12, 11077–11083. doi:10.2147/CMAR.S278673

Tajan, M., and Vousden, K. H. (2020). Dietary Approaches to Cancer Therapy. Cancer Cell 37, 767–785. doi:10.1016/j.ccell.2020.04.005

Tammi, R., Pasonen-Seppänen, S., Kolehmainen, E., and Tammi, M. (2005). Hyaluronan Synthase Induction and Hyaluronan Accumulation in Mouse Epidermis Following Skin Injury. J. Invest. Dermatol. 124, 898–905. doi:10.1111/j.0022-202X.2005.23697.x

Thorens, B., and Mueckler, M. (2010). Glucose Transporters in the 21st Century. Am. J. Physiol. Endocrinol. Metab. 298, E141–E145. doi:10.1152/ajpendo.00712.2009

Tian, S., Peng, P., Li, J., Deng, H., Zhan, N., Zeng, Z., et al. (2020). SERPINH1 Regulates EM7 and Gastric Cancer Metastasis via the Wnt/β-Catenin Signaling Pathway. Aging (Albany NY) 12, 3574–3593. doi:10.18632/aging.102831

Torretta, S., Scagliola, A., Ricci, L., Mainini, F., Di Marco, S., Cuccovillo, I., et al. (2020). D-mannose Suppresses Macrophage IL-1β Production. Nat. Commun. 11, 6343. doi:10.1038/s41467-020-20164-6

Wang, Y., Xie, S., and He, B. (2020). Mannose Shows Antitumour Properties against Lung Cancer via Inhibiting Proliferation, Promoting Caspase-mediated Apoptosis and Reducing Metastasis. Mol. Med. Rep. 22, 2957–2965. doi:10.3892/mmr.2020.11354

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., and Sancho, D. (2020). Dendritic Cells in Cancer Immunology and Immunotherapy. Nat. Rev. Immunol. 20, 7–24. doi:10.1038/s41577-019-0210-z

Wei, Z., Huang, L., Cui, L., and Zhu, X. (2020). Mannose: Good Player and Assister in Pharmacotherapy. Biomed. Pharmacother. 129, 110420. doi:10.1016/j.biopharm.2020.110420

Wu, H., Zhang, W., and Mu, W. (2019). Recent Studies on the Biological Production of D-Mannose. Appl. Microbiol. Biotechnol. 103, 8753–8761. doi:10.1007/s00253-019-10151-3

Yu, J., Wang, S., Qi, J., Yu, Z., Xian, Y., Liu, W., et al. (2021). Mannose-modified Liposome Designed for Epitope Peptide Drug Delivery in Cancer Immunotherapy. Int. Immunopharmacol. 101, 108148. doi:10.1016/j.intimp.2021.108148

Zhang, D., Chia, C., Jiao, X., Jin, W., Kasagi, S., Wu, R., et al. (2017). D-mannose Induces Regulatory T Cells and Suppresses Immunoapathology. Nat. Med. 23, 1036–1045. doi:10.1038/nm.4373

Zhang, W., Cheng, H., Gui, Y., Zhan, Q., Li, S., Qiao, W., et al. (2021). Mannose Treatment: A Promising Novel Strategy to Suppress Inflammation. Front. Immunol. 12, 756920. doi: 10.3389/fimmu.2021.756920

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Nan, Sun, Liang, Zhou, Ma and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.